The Solid Tumor Fusion/Expression Profile provides clinically relevant information on translocations and expression of cancer-specific genes. This assay is designed to detect various translocations involving more than 60 genes, including ALK, ROS1, RET, NTRK1, NTRK2, NTRK3, BRAF, CIC, EWSR1, PD-L1, and others. This also covers screening for sarcoma translocations and aids in sarcoma diagnosis and classification. In addition, the expression of genes of clinical relevance is reported including MYC, PD-L1, and others.